SCHEMBL2206499

SCHEMBL2206499

N#CCC(O)c1cccc(OCc2c(Cl)cccc2Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
OPRK1 P41145 1/20 0.42
NR1H4 Q96RI1 3/20 0.39
NPC1 O15118 1/20 0.39
NR4A2 P43354 1/20 0.39
RAB9A P51151 1/20 0.39
SGMS2 Q8NHU3 1/20 0.38
MAPK1 P28482 2/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
MEN1 O00255 1/20 0.36
GMNN O75496 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetonitrile SCHEMBL27996028 0.96 NR1H4 (0.40) SMN1; SMN2OPRK1NR1H4NPC1NR4A2
SCHEMBL4594568 0.81 SGMS2 (0.57) SMN1; SMN2NR4A2SGMS2MAPK1TSHR
SCHEMBL16031060 0.81 SGMS2 (0.57) SMN1; SMN2NR4A2SGMS2MAPK1TSHR
SCHEMBL2205552 0.80 SMN1; SMN2 (0.43) SMN1; SMN2OPRK1MAPK1TP53CYP1A2
SCHEMBL29818761 0.80 SMN1; SMN2 (0.43) SMN1; SMN2OPRK1MAPK1TP53CYP1A2
SCHEMBL4568934 0.80 MAPK1 (0.49) SMN1; SMN2OPRK1MAPK1TP53CYP1A2
SCHEMBL16032686 0.80 KMT2A (0.40) SMN1; SMN2SGMS2MAPK1TP53CYP1A2
SCHEMBL16032684 0.80 KMT2A (0.40) SMN1; SMN2SGMS2MAPK1TP53CYP1A2
SCHEMBL21205744 0.77 KMT2A (0.43) SMN1; SMN2NPC1NR4A2RAB9AKMT2A
SCHEMBL29818824 0.77 PRSS1 (0.38) SMN1; SMN2TSHRALDH1A1LMNAALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12029708-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2024-07-09 US disclosed
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2023-07-13 US disclosed
US-11446261-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2022-09-20 US disclosed
US-20210077427-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2021-03-18 US disclosed
US-10639286-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2020-05-05 US disclosed
US-20190183816-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2019-06-20 US disclosed
US-10188615-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2019-01-29 US disclosed
US-20180177746-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2018-06-28 US disclosed
EP-3210966-A1 ALKOXYPHENYLPROPYLAMINES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Acucela, Inc. (US) 2017-08-30 EP disclosed
US-9737496-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2017-08-22 US disclosed
US-8993807-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2015-03-31 US disclosed
US-8981153-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2015-03-17 US disclosed
CN-103553945-B Alkoxy compounds for disease treatment ACUCELA INC 2015-01-07 CN disclosed
US-8829244-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2014-09-09 US disclosed
US-20130197096-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA, INC. (US) 2013-08-01 US disclosed
US-20120214852-A1 Alkoxy Compounds for Disease Treatment ACUCELA INC. (US) 2012-08-23 US disclosed
US-20120129894-A1 Alkoxy Compounds for Disease Treatment ACUCELA INC. (US) 2012-05-24 US disclosed
US-20120122938-A1 Alkoxy Compounds for Disease Treatment ACUCELA INC. (US) 2012-05-17 US disclosed
US-7982071-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2011-07-19 US disclosed
US-20090326074-A1 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12029708-B2 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER SMN1; SMN2 42/4885OPRK1 1504/4885NR1H4 1808/4885
US-20120122938-A1 Alkoxy Compounds for Disease Treatment ALDH1A2, CLN6, AGER SMN1; SMN2 42/4885OPRK1 1504/4885NR1H4 1808/4885
US-20210077427-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER SMN1; SMN2 42/4885OPRK1 1504/4885NR1H4 1808/4885
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER SMN1; SMN2 39/4885OPRK1 1524/4885NR1H4 1836/4885
US-20190183816-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER SMN1; SMN2 42/4885OPRK1 1504/4885NR1H4 1808/4885
US-20130197096-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER SMN1; SMN2 42/4885OPRK1 1504/4885NR1H4 1808/4885
US-11446261-B2 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER SMN1; SMN2 42/4885OPRK1 1504/4885NR1H4 1808/4885
US-20120214852-A1 Alkoxy Compounds for Disease Treatment ALDH1A2, CLN6, AGER SMN1; SMN2 42/4885OPRK1 1504/4885NR1H4 1808/4885
US-20090326074-A1 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER SMN1; SMN2 42/4885OPRK1 1504/4885NR1H4 1808/4885
US-10188615-B2 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER SMN1; SMN2 42/4885OPRK1 1504/4885NR1H4 1808/4885
US-20180177746-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER SMN1; SMN2 42/4885OPRK1 1504/4885NR1H4 1808/4885
US-20120129894-A1 Alkoxy Compounds for Disease Treatment ALDH1A2, CLN6, AGER SMN1; SMN2 42/4885OPRK1 1504/4885NR1H4 1808/4885
US-10639286-B2 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER SMN1; SMN2 42/4885OPRK1 1504/4885NR1H4 1808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.